Profile
Sector:
HealthcareCountry:
United StatesIPO:
28 September 2007Website:
http://www.harrow.comNext earnings report:
19 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 20 Nov 2024 00:52:51 GMTDividend
Analysts recommendations
Institutional Ownership
HROW Latest News
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following three investor conferences: Craig-Hallum 15th Annual Alpha Select Conference (Sheraton New York Times Square Hotel) November 19, 2024 1x1 Meetings Only BTIG 4th Annual Ophthalmology Day (Virtual) December 2, 2024 1x1 Virtual Meetings Only Piper Sandler 36th Annual Healthcare Conference (The Lotte New York Palace) Dec.
Harrow, Inc. (NASDAQ:HROW ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Jamie Webb - Director, Communications & Investor Relations Mark Baum - CEO Andrew Boll - CFO Conference Call Participants Chase Knickerbocker - Craig Hallum Brooks O'Neil - Lake Street Capital Markets Jeffrey Cohen - Ladenburg Thalmann & Company Mayank Mamtani - B. Riley Securities Operator Good morning, and welcome to Harrow's Third Quarter 2024 Earnings Conference Call.
Harrow (HROW) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.09 per share a year ago.
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the third quarter and nine months ended September 30, 2024. The Company also posted its third quarter Letter to Stockholders and corporate presentation to the “Investors” section of its website, harrow.com. The Company encourages all Harrow stockholders to review these documents, which provide additional details concerning the historical quarterly period and f.
Harrow Inc. experienced a brief 20% stock drop in October but quickly recovered, showing resilience despite recent revenue channel underperformance. HROW's new branded pharmaceutical products, especially VEVYE, are driving a diversified revenue stream, with VEVYE showing exceptional growth and market penetration since its late 2023 launch. VEVYE's strong refill rates and expanding prescriber base indicate significant patient benefits and long-term revenue potential, supported by a patent extending to 2039.
Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HROW, ORLA and SWDBY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 6, 2024.
Harrow (HROW) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The average of price targets set by Wall Street analysts indicates a potential upside of 26% in Harrow (HROW). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Harrow (HROW) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
- 1(current)
- 2
What type of business is Harrow Health?
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. Further, the company has collaboration with Asembia to enhance provider and patient experience through nationwide digital services and hub support for harrow's branded eyecare products. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
What sector is Harrow Health in?
Harrow Health is in the Healthcare sector
What industry is Harrow Health in?
Harrow Health is in the Drug Manufacturers - Specialty & Generic industry
What country is Harrow Health from?
Harrow Health is headquartered in United States
When did Harrow Health go public?
Harrow Health initial public offering (IPO) was on 28 September 2007
What is Harrow Health website?
https://www.harrow.com
Is Harrow Health in the S&P 500?
No, Harrow Health is not included in the S&P 500 index
Is Harrow Health in the NASDAQ 100?
No, Harrow Health is not included in the NASDAQ 100 index
Is Harrow Health in the Dow Jones?
No, Harrow Health is not included in the Dow Jones index
When was Harrow Health the previous earnings report?
No data
When does Harrow Health earnings report?
The next expected earnings date for Harrow Health is 19 March 2025